leChRO-seq in L3.6pl (Parental and Paclitaxel-resistant)
收藏官方服务：
资源简介：
leChRO-seq in L3.6pl (Parental and Paclitaxel-resistant)
应用场景：
创建时间：
2023-03-24
相关数据集
Additional file 7 of Novel drug resistance mechanisms and drug targets in BRAF-mutated peritoneal metastasis from colorectal cancer
Supplementary Material 7.
DataCite Commons2024-08-17 更新90
Expression data from human cell lines before and after treated with drugs.
Analysis of HER2-amplified NCI-N87 gastric cancer cell line exposed to 0.1 µg/mL T-DM1 and subsequently cultured in the presence of gradually increasing doses, up to a maximum of 4 µg/mL. The resultan
NIAID Data Ecosystem20
Additional file 1: of Tunicamycin specifically aggravates ER stress and overcomes chemoresistance in multidrug-resistant gastric cancer cells by inhibiting N-glycosylation
Table S1. CI values for SGC7901, SGC7901/ADR and SGC7901/VCR. CI was calculated by CompuSyn, which is based on the model created by Chou and Talalay. CI 1 represent synergism, add
NIAID Data Ecosystem20
Suppression of adaptive responses to targeted cancer therapy by transcriptional repression [RNA-seq]. Homo sapiens
Large-scale genomic profiling efforts have facilitated the characterization of molecular alterations in cancers and aided the development of targeted kinase inhibitors for a wide array of cancer types
NIAID Data Ecosystem50
Fusion genes in EGFR mutant lung cancer
The clinical significance of gene fusions detected by DNA-based next generation sequencing remains unclear as resistance mechanisms to EGFR tyrosine kinase inhibitors (TKIs) in EGFR mutant non-small c
NIAID Data Ecosystem20
